Interaction of CmeABC and CmeDEF in conferring antimicrobial resistance and maintaining cell viability in Campylobacter jejuni

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 1, 2006, Pages 52-60

  Akiba, Masato ^a,b   Lin, Jun ^a,c   Barton, Yi Wen ^a   Zhang, Qijing ^a  

^a IOWA STATE UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ANIMAL HEALTH   (Japan)

^c UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Antibiotics; Efflux; Mutagenesis

Indexed keywords

ACRIFLAVINE; AMPICILLIN; ANTIBIOTIC AGENT; CEFOTAXIME; CHENODEOXYCHOLIC ACID; CHOLIC ACID; CIPROFLOXACIN; DEOXYCHOLIC ACID; ERYTHROMYCIN; ETHIDIUM BROMIDE; FUSIDIC ACID; GENTAMICIN; GLYCOCHOLIC ACID; GLYCOPROTEIN P; NOVOBIOCIN; POLYMYXIN B; POLYSORBATE 20; PROTAMINE; RIFAMPICIN; TAUROCHOLIC ACID; TETRACYCLINE; TOXIC SUBSTANCE; TRITON X 100; ZINC SULFATE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASSAY; BACTERIAL GROWTH; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM MUTANT; CAMPYLOBACTER JEJUNI; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; NONHUMAN; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; WILD TYPE;

ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; BETA-GALACTOSIDASE; CAMPYLOBACTER JEJUNI; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL; MEMBRANE FUSION PROTEINS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MUTAGENESIS, INSERTIONAL; PLASMIDS;

EID: 30344434342     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki419     Document Type: Article

References (24)

1. Friedman CR, Neimann J, Wegener HC et al. Epidemiology of Campylobacter jejuni infections in the United States and other industrialized nations. In: Nachamkin I, Blaser MJ, eds. Campylobacter. Washington, DC: ASM Press, 2000; 121-38.
2. Nachamkin I, Allos BM, Ho TW. Campylobacter jejuni infection and the association with Guillain-Barre syndrome. In: Nachamkin I, Blaser MJ, eds. Campylobacter. Washington, DC: ASM Press, 2000; 155-75.
3. Newell DG, Wagenaar JA. Poultry infections and their control at the farm level. In: Nachamkin I, Blaser MJ, eds. Campylobacter. Washington, DC: ASM Press, 2000; 497-509.
4. Engberg J, Aarestrup FM, Taylor DE et al. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: Resistance mechanisms and trends in human isolates. Emerg Infect Dis 2001; 7: 24-34.
5. Lin J, Akiba M, Zhang QJ. Multidrug efflux systems in Campylobacter. In: Ketley JM, Konkel ME, eds. Campylobacter: Molecular and Cellular Biology. Norfolk: Horizon BioScience, 2005; 205-18.
6. Tayler DE, Tracz DM. Mechanisms of antimicrobial resistance in Campylobacter. In: Ketley JM, Konkel ME, eds. Campylobacter: Molecular and Cellular Biology. Norfolk: Horizon BioScience, 2005; 193-204.
7. Lin J, Michel LO, Zhang Q. CmeABC functions as a multidrug efflux system in Campylobacter jejuni. Antimicrob Agents Chemother 2002; 46: 2124-31.
8. Pumbwe L, Piddock LJ. Identification and molecular characterisation of CmeB, a Campylobacter jejuni multidrug efflux pump. FEMS Microbiol Lett 2002; 206: 185-9.
9. Payot S, Cloeckaert A, Chaslus-Dancla E. Selection and characterization of fluoroquinolone-resistant mutants of Campylobacter jejuni using enrofloxacin. Microb Drug Resist 2002; 8: 335-43.
10. Luo N, Sahin O, Lin J et al. In vivo selection of Campylobacter isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux pump. Antimicrob Agents Chemother 2003; 47: 390-4.
11. Lin J, Sahin O, Michel LO et al. Critical role of multidrug efflux pump CmeABC in bile resistance and in vivo colonization of Campylobacter jejuni. Infect Immun 2003; 71: 4250-9.
12. Lin J, Akiba M, Sahin O et al. CmeR functions as a transcriptional repressor for the multidrug efflux pump CmeABC in Campylobacter jejuni. Antimicrob Agents Chemother 2005; 49: 1067-75.
13. Parkhill J, Wren BW, Mungall K et al. The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences. Nature 2000; 403: 665-8.
14. Pumbwe L, Randall LP, Woodward MJ et al. Evidence for multiple-antibiotic resistance in Campylobacter jejuni not mediated by Cmeb or CmeF. Antimicrob Agents Chemother 2005; 49: 1289-93.
15. Ge B, McDermott PF, White DG et al. Role of efflux pumps and topoisomerase mutations in fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother 2005; 49: 3347-54.
16. Wang Y, Taylor DE. Chloramphenicol resistance in Campylobacter coli: nucleotide sequence, expression, and cloning vector construction. Gene 1990; 94: 23-8.
17. Wang Y, Taylor DE. Natural transformation in Campylobacter species. J Bacteriol 1990; 172: 949-55.
18. Zhang Q, Meitzler JC, Huang S et al. Sequence polymorphism, predicted secondary structures, and surface-exposed conformational epitopes of Campylobacter major outer membrane protein. Infect Immun 2000; 68: 5679-89.
19. Blaser MJ, Hopkins JA, Berka RM et al. Identification and characterization of Campylobacter jejuni outer membrane proteins. Infect Immun 1983; 42: 276-84.
20. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
21. Wosten MM, Boeve M, Koot MG et al. Identification of Campylobacter jejuni promoter sequences. J Bacteriol 1998; 180: 594-9.
22. Miller WG, Bates AH, Horn ST et al. Detection on surfaces and in Caco-2 cells of Campylobacter jejuni cells transformed with new gfp, yfp, and cfp marker plasmids. Appl Environ Microbiol 2000; 66: 5426-36.
23. Miller JH. A Short Course in Bacterial Genetics: A Laboratory Manual and Handbook for Escherichia coli and Related Bacteria. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 1992.
24. Black RE, Levine MM, Clements ML et al. Experimental Campylobacter jejuni infection in humans. J Infect Dis 1988; 157: 472-9.